ZYME Zymeworks Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$25.15
· of 52w range
· above low
· to high
$16.0052w low
$31.3452w high
Market Cap (MRQ)
$1.80B
P/E (TTM)
-12.5
EPS (TTM)
$-2.02
Revenue (TTM)
$37M
your badges
52W Range
$16–$31
Analyst Rating
BUY
Price Target
$41
P/E
-12.5
ROE
-72.3%
Net Profit Margin
-404.0%
Your badge strip is empty — pin a metric anywhere on this page.
ZYME Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$25.15
Market Cap (MRQ)
$1.80B
P/E (TTM)
-12.5
EPS (TTM)
$-2.02
Revenue (TTM)
$37M
ROE (TTM)
-72.3%
52W Range
$16–$31
ZYME Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Zymeworks Inc. - Common Stock Company overview from Wikipedia
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.
In September 2019, Zymeworks announced that, following their clinical trials, it has been confirmed that their ZW25 monotherapy can provide durable disease control in patients with a variety of HER2-expressing solid tumors that have progressed following standard of care treatments.
In May 2022, Zymeworks rejected an unsolicited takeover proposal from a Dubai hedge fund, All Blue Falcons FZE, an arm of All Blue Capital.
Azymetric
This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1. This scaffold can also be engineered with tailored effector function and optimized serum half-life.
Awards and recognition
Deal of the Year, Lifesciences BC Awards, 2018
Life Sciences Company of the Year, Lifesciences BC Awards, 2016
Emerging company of the year – Health, BIOTECanada Gold Leaf Awards, 2015
12th Place, BC's Leading Innovators, 2011
Life Science Emerging Rocket, 2009, 2010, 2011
Early stage Company of the year – Industrial & Agriculture, BIOTECanada Gold Leaf Awards, 2009
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees231
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$106M2020-12-31 → 2025-12-31
EPS$-1.082020-12-31 → 2025-12-31
Free Cash Flow$-35M2023-12-31 → 2025-12-31
Net margin-404.0%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ZYME | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -12.55Y avg ≈-8.8 | ≈-8.8 | · | · | |
| P/S (TTM) | 48.45Y avg ≈13.8 | ≈13.8 | 10.3 | Overvalued | |
| P/B (MRQ) | 22.35Y avg ≈4.0 | ≈4.0 | 3.7 | Overvalued | |
| Price / FCF (TTM) | -14.95Y avg ≈-24.0 | ≈-24.0 | · | · | |
| Price / Cash Flow (TTM) | -15.05Y avg ≈-25.0 | ≈-25.0 | · | · | |
| Price / Tangible Book (MRQ) | 22.65Y avg ≈3.4 | ≈3.4 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ZYME | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -419.0%5Y avg ≈-149.5% | ≈-149.5% | -588.2% | Weak | |
| EBITDA Margin | -87.3%5Y avg ≈-149.5% | ≈-149.5% | -588.2% | Weak | |
| Pretax Margin (TTM) | -407.8%5Y avg ≈-128.3% | ≈-128.3% | -709.2% | Weak | |
| Net Profit Margin (TTM) | -404.0%5Y avg ≈-131.2% | ≈-131.2% | -507.2% | Weak | |
| ROA (TTM) | -37.2%5Y avg ≈-21.0% | ≈-21.0% | -29.6% | Top tier | |
| ROE (TTM) | -72.3%5Y avg ≈-29.5% | ≈-29.5% | -42.0% | Top tier | |
| ROIC | -35.1%5Y avg ≈-35.7% | ≈-35.7% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ZYME | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 6.35Y avg ≈5.6 | ≈5.6 | 9.0 | Low liquidity | |
| Quick Ratio | 1.15Y avg ≈3.2 | ≈3.2 | 5.8 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ZYME | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 38.9%5Y avg ≈274.4% | ≈274.4% | · | · | |
| Revenue CAGR 3Y | -36.4%5Y avg ≈10.2% | ≈10.2% | · | · | |
| Revenue CAGR 5Y | 22.2% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ZYME | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.35Y avg ≈0.2 | ≈0.2 | 0.2 | Top tier | |
| Receivables Turnover | 3.55Y avg ≈2.8 | ≈2.8 | · | · | |
| Revenue / Employee | ≈$458.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-16.9%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-0.62 | $-0.50 | -25.1% |
| March 31, 2026 | May 6, 2026 | $-0.59 | $-0.20 | -201.3% |
| Dec. 31, 2025 | $-0.55 | $-0.42 | -29.5% | |
| Sept. 30, 2025 | $-0.26 | $-0.33 | 20.6% | |
| June 30, 2025 | $0.03 | $-0.50 | 106.0% | |
| March 31, 2025 | $-0.30 | $-0.42 | 28.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $106M | $76M | $76M | $412M | $27M | |
| R&D Expense | · | · | $144M | $209M | $200M | |
| SG&A Expense | $62M | $62M | $70M | $73M | $43M | |
| Operating Expenses | $199M | $213M | $214M | $282M | $242M | |
| Operating Income | $-93M | $-137M | $-138M | $131M | $-216M | |
| Other Non-op | $51.0K | $-218.0K | $291.0K | $-42.0K | $118.0K | |
| Pretax Income | $-80M | $-117M | $-119M | $135M | $-212M | |
| Income Tax | $1M | $6M | $-568.0K | $11M | $-516.0K | |
| Net Income | $-81M | $-123M | $-119M | $124M | $-212M | |
| EPS (Basic) | $-1.08 | $-1.62 | $-1.72 | $1.91 | $-4.11 | |
| EPS (Diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 | |
| Shares (Basic) | 75,404,897 | 75,846,681 | 68,863,010 | 65,194,775 | 51,553,869 | |
| Shares (Diluted) | 75,413,396 | 75,878,738 | 68,863,010 | 65,249,184 | 52,131,596 | |
| EBITDA | $-93M | $-137M | $-138M | · | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $66M | $158M | $401M | $202M | |
| Short-term Investments | · | · | $217M | $91M | $51M | |
| Receivables | $5M | $56M | $19M | $33M | $16M | |
| Prepaid Expense | $15M | $19M | $19M | $19M | $20M | |
| Current Assets | $249M | $300M | $413M | $545M | $288M | |
| PP&E (Net) | $16M | $18M | $20M | $25M | $23M | |
| PP&E (Gross) | $36M | $35M | $41M | $38M | $37M | |
| Accum. Depreciation | $21M | $18M | $21M | $13M | $14M | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | |
| Intangibles | $1M | $5M | $8M | $9M | $4M | |
| Total Assets | $347M | $463M | $581M | $649M | $389M | |
| Accounts Payable | $36M | $60M | $46M | $87M | $63M | |
| Current Liabilities | $42M | $88M | $56M | $96M | $72M | |
| Capital Leases | $15M | $16M | $22M | $25M | $31M | |
| Deferred Tax | $6M | $5M | $3M | $2M | $2M | |
| Other Non-current Liabilities | $278.0K | $923.0K | $2M | $3M | $3M | |
| Total Liabilities | $78M | $124M | $116M | $156M | $140M | |
| Common Stock | $1.11B | $1.02B | $997M | $886M | $741M | |
| Retained Earnings | $-953M | $-830M | $-677M | $-559M | $-683M | |
| AOCI | $-6M | $-7M | $-7M | $-7M | $-7M | |
| Stockholders' Equity | $269M | $339M | $465M | $493M | $249M | |
| Liabilities + Equity | $347M | $463M | $581M | $649M | $389M | |
| Shares Outstanding | 74,638,413 | 68,964,319 | 70,115,997 | 63,059,501 | 46,633,935 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $28M | $18M | $8M | $4M | $11M | |
| Deferred Tax | $945.0K | $691.0K | $-757.0K | $2M | $-953.0K | |
| Amort. of Intangibles | $4M | $4M | $3M | $1M | $3M | |
| Restructuring | · | · | $0 | · | · | |
| Operating Cash Flow | $-33M | $-110M | $-118M | $144M | $-192M | |
| CapEx | $2M | $2M | $2M | $8M | $12M | |
| Investing Cash Flow | $27M | $39M | $-207M | $-54M | $145M | |
| Stock Issued | $0 | $0 | $26M | $108M | $0 | |
| Stock Repurchased | $42M | $30M | $0 | $0 | · | |
| Net Stock Activity | $-42M | $-30M | $26M | · | · | |
| Financing Cash Flow | $-19M | $-20M | $82M | $109M | $8M | |
| Net Change in Cash | $-25M | $-91M | $-243M | $199M | $-40M | |
| Taxes Paid | $1M | $3M | $165.0K | $10M | · | |
| Free Cash Flow | $-35M | $-112M | $-121M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Margin | -87.3% | -179.7% | -181.6% | · | · | |
| Net Margin | -76.6% | -160.8% | -156.1% | · | · | |
| Pretax Margin | -75.3% | -152.8% | -156.9% | · | · | |
| EBITDA Margin | -87.3% | -179.7% | -181.6% | · | · | |
| ROA | -20.0% | -23.5% | -19.3% | · | · | |
| ROE | -26.9% | -34.8% | -26.7% | · | · | |
| ROIC | -35.1% | -42.6% | -29.6% | · | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.9 | 3.4 | 7.4 | · | · | |
| Quick Ratio | 1.1 | 1.4 | 7.1 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 3.5 | 2.0 | 2.9 | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Book Value / Share | $3.60 | $4.91 | $6.63 | · | · | |
| Revenue / Share | $1.41 | $1.01 | $1.10 | · | · | |
| Cash Flow / Share | $-0.44 | $-1.45 | $-1.72 | · | · | |
| Cash / Share | $0.55 | $0.96 | $2.25 | · | · | |
| EPS (TTM) | $-1.08 | $-1.62 | $-1.72 | $1.90 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue YoY | 38.9% | 0.38% | -81.6% | 1446.0% | -31.5% | |
| Revenue CAGR 3Y | -36.4% | 41.9% | 25.0% | · | · | |
| Revenue CAGR 5Y | 22.2% | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $106M | $76M | $76M | $412M | · | |
| Net Income TTM | $-81M | $-123M | $-119M | $124M | · | |
| Market Cap | $1.97B | $1.01B | $729M | · | · | |
| P/E | -24.4 | -9.0 | -6.0 | 4.1 | · | |
| P/S | 18.5 | 13.2 | 9.6 | · | · | |
| P/B | 7.3 | 3.0 | 1.6 | · | · | |
| P / Tangible Book | 7.7 | 3.1 | 1.6 | 1.0 | · | |
| P / Cash Flow | -59.5 | -9.2 | -6.2 | · | · | |
| P / FCF | -56.9 | -9.0 | -6.0 | · | · | |
| Earnings Yield | -4.1% | -11.1% | -16.6% | 24.2% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $2M | $3M | $28M | $49M | $27M | $31M | $16M | $19M | $10M | $17M | $17M | $7M | $36M | $402M | $3M | |
| R&D Expense | · | · | · | · | · | · | · | · | · | $32M | · | $33M | $39M | $46M | · | $37M | |
| SG&A Expense | $19M | $15M | $15M | $14M | $15M | $17M | $16M | $14M | $16M | $16M | $15M | $17M | $22M | $17M | $30M | $16M | |
| Operating Expenses | $47M | $50M | $47M | $50M | $49M | $53M | $53M | $50M | $62M | $48M | $40M | $50M | $61M | $63M | $83M | $53M | |
| Operating Income | $-42M | $-47M | $-44M | $-22M | $-674.0K | $-26M | $-22M | $-34M | $-43M | $-38M | $-23M | $-33M | $-54M | $-27M | $319M | $-50M | |
| Other Non-op | $196.0K | $120.0K | $-18.0K | $26.0K | $-621.0K | $49.0K | $-253.0K | $-37.0K | $53.0K | $19.0K | $-278.0K | $370.0K | $230.0K | $-31.0K | $-27.0K | $-98.0K | |
| Pretax Income | $-45M | $-46M | $-41M | $-18M | $2M | $-22M | $-18M | $-30M | $-38M | $-32M | $-19M | $-28M | $-49M | $-23M | $320M | $-48M | |
| Income Tax | $-273.0K | $-2M | $-270.0K | $1M | $-186.0K | $496.0K | $6M | $226.0K | $68.0K | $75.0K | $-5M | $1M | $2M | $1M | $11M | $-29.0K | |
| Net Income | $-45M | $-44M | $-41M | $-20M | $2M | $-23M | $-24M | $-30M | $-38M | $-32M | $-14M | $-29M | $-51M | $-24M | $309M | $-48M | |
| EPS (Basic) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.19 | $-0.41 | $-0.76 | $-0.36 | $4.78 | $-0.72 | |
| EPS (Diluted) | $-0.62 | $-0.59 | $-0.55 | $-0.26 | $0.03 | $-0.30 | $-0.32 | $-0.39 | $-0.49 | $-0.42 | $-0.18 | $-0.41 | $-0.76 | $-0.37 | $4.78 | $-0.72 | |
| Shares (Basic) | 72,993,313 | 74,668,790 | · | 75,767,778 | 75,337,168 | 75,171,020 | · | 76,128,531 | 76,392,593 | 76,214,833 | · | 70,575,773 | 67,281,028 | 66,739,308 | · | 66,477,016 | |
| Shares (Diluted) | 72,993,313 | 74,694,762 | · | 75,775,214 | 77,378,449 | 75,226,387 | · | 76,157,101 | 76,396,217 | 76,248,158 | · | 70,575,773 | 67,284,511 | 66,742,030 | · | 66,478,157 | |
| EBITDA | $-42M | $-47M | · | $-22M | $-674.0K | $-26M | · | $-34M | $-43M | $-38M | · | $-33M | $-54M | $-27M | · | $-50M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $179M | $244M | $41M | $65M | $98M | $76M | $66M | $122M | $71M | $115M | · | $94M | $142M | $182M | · | $96M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $201M | $198M | $159M | · | $70M | |
| Receivables | $6M | $5M | $5M | $29M | $3M | $25M | $56M | $24M | $32M | $31M | · | $67M | $49M | $67M | · | $7M | |
| Prepaid Expense | $22M | $16M | $15M | $10M | $12M | $17M | $19M | $23M | $21M | $18M | · | $12M | $31M | $19M | · | $18M | |
| Current Assets | $298M | $386M | $249M | $292M | $296M | $306M | $300M | $344M | $383M | $394M | · | $375M | $420M | $426M | · | $191M | |
| PP&E (Net) | $14M | $15M | $16M | $16M | $16M | $17M | $18M | $18M | $18M | $19M | · | $21M | $22M | $24M | · | $26M | |
| PP&E (Gross) | · | · | $36M | · | · | · | $35M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $21M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Intangibles | $998.0K | $1M | $1M | $1M | $2M | $3M | $5M | $6M | $7M | $7M | · | $8M | $7M | $8M | · | $9M | |
| Total Assets | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Accounts Payable | $27M | $30M | $36M | $34M | $31M | $38M | $60M | $52M | $44M | $47M | · | $68M | $70M | $59M | · | $52M | |
| Current Liabilities | $47M | $36M | $42M | $42M | $39M | $65M | $88M | $84M | $55M | $57M | · | $73M | $94M | $67M | · | $58M | |
| Capital Leases | $13M | $14M | $15M | $16M | $15M | $15M | $16M | $17M | $17M | $21M | · | $22M | $23M | $24M | · | $25M | |
| Deferred Tax | $4M | $4M | $6M | $5M | $5M | $5M | $5M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Other Non-current Liabilities | $278.0K | $278.0K | $278.0K | $278.0K | $828.0K | $856.0K | $923.0K | $929.0K | $1M | $2M | · | $2M | $4M | $4M | · | $3M | |
| Total Liabilities | $317M | $315M | $78M | $77M | $74M | $101M | $124M | $120M | $109M | $116M | · | $132M | $153M | $127M | · | $121M | |
| Common Stock | $1.13B | $1.13B | $1.11B | $1.09B | $1.07B | $1.02B | $1.02B | $1.01B | $1.01B | $1.00B | · | $932M | $929M | $900M | · | $885M | |
| Retained Earnings | $-1.17B | $-1.07B | $-953M | $-886M | $-851M | $-853M | $-830M | $-798M | $-747M | $-709M | · | $-663M | $-634M | $-583M | · | $-868M | |
| AOCI | $-7M | $-7M | $-6M | $-6M | $-6M | $-6M | $-7M | $-6M | $-8M | $-8M | · | $-8M | $-8M | $-6M | · | $-7M | |
| Stockholders' Equity | $80M | $164M | $269M | $320M | $335M | $325M | $339M | $367M | $406M | $438M | $465M | $424M | $449M | $474M | $493M | $180M | |
| Liabilities + Equity | $397M | $478M | $347M | $397M | $408M | $426M | $463M | $487M | $516M | $554M | · | $556M | $602M | $601M | · | $300M | |
| Shares Outstanding | 71,412,072 | 73,102,689 | 74,638,413 | 75,139,281 | 74,846,147 | 69,584,811 | 68,964,319 | 69,584,882 | 70,831,545 | 70,677,106 | · | 67,922,559 | 67,687,384 | 64,083,770 | · | 61,694,387 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $11M | $7M | $9M | $7M | $6M | $6M | $5M | $5M | $5M | $4M | $3M | $2M | $367.0K | $2M | $4M | $5M | |
| Amort. of Intangibles | $176.0K | $176.0K | $185.0K | $648.0K | $2M | $2M | $2M | $980.0K | $812.0K | $702.0K | $673.0K | $672.0K | $678.0K | $679.0K | $529.0K | $166.0K | |
| Operating Cash Flow | $-32M | $-46M | $-10M | $-31M | $12M | $-3M | $-42M | $-6M | $-25M | $-38M | $14M | $-43M | $-6M | $-83M | $327M | $-73M | |
| CapEx | $0 | $216.0K | $581.0K | $410.0K | $514.0K | $16.0K | $314.0K | $899.0K | $593.0K | $185.0K | $356.0K | $930.0K | $802.0K | $386.0K | $348.0K | $981.0K | |
| Investing Cash Flow | $17M | $70M | $5M | $368.0K | $9M | $12M | $-6M | $72M | $-20M | $-7M | $-1M | $-7M | $-61M | $-138M | $-22M | $-30M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | · | · | $0 | $0 | $26M | $0 | $0 | $0 | |
| Stock Repurchased | $52M | $76M | $25M | $16M | $0 | $0 | $9M | · | · | · | $0 | · | · | · | · | · | |
| Net Stock Activity | · | $-76M | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $-50M | $179M | $-19M | $-2M | $1M | $1M | $-9M | $-15M | $1M | $2M | $51M | $2M | $28M | $2M | $-377.0K | $628.0K | |
| Net Change in Cash | $-65M | $203M | $-24M | $-33M | $22M | $10M | $-56M | $51M | $-44M | $-43M | $63M | $-48M | $-39M | $-219M | $305M | $-103M | |
| Taxes Paid | $863.0K | $245.0K | $107.0K | $660.0K | $196.0K | $387.0K | $3M | $106.0K | $106.0K | $0 | · | · | · | · | · | · | |
| Free Cash Flow | · | $-46M | · | · | · | $-3M | · | · | · | $-38M | · | · | · | $-84M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| Net Margin | -980.8% | -1834.0% | · | -71.0% | 4.8% | -83.5% | · | -186.6% | -195.8% | -315.6% | · | -173.8% | -730.5% | -68.5% | · | -1818.6% | |
| Pretax Margin | -986.8% | -1925.0% | · | -66.1% | 4.4% | -81.7% | · | -185.2% | -195.5% | -314.8% | · | -167.1% | -706.9% | -64.5% | · | -1819.7% | |
| EBITDA Margin | -919.0% | -1956.7% | · | -80.1% | -1.4% | -94.5% | · | -213.8% | -222.9% | -376.9% | · | -201.4% | -772.8% | -76.7% | · | -1914.0% | |
| ROA | -11.2% | -9.8% | · | -4.4% | 0.50% | -4.6% | · | -5.7% | -6.7% | -5.5% | · | -6.7% | -17.0% | -8.1% | · | -31.9% | |
| ROE | -21.7% | -18.1% | · | -5.7% | 0.63% | -5.9% | · | -7.5% | -8.8% | -6.9% | · | -9.5% | -22.8% | -10.3% | · | -53.2% | |
| ROIC | -52.2% | -27.4% | · | -7.4% | -0.22% | -8.1% | · | -9.4% | -10.6% | -8.6% | · | -8.2% | -12.5% | -6.1% | · | -28.0% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 10.8 | · | 6.9 | 7.7 | 4.7 | · | 4.1 | 7.0 | 6.9 | · | 5.1 | 4.5 | 6.3 | · | 3.3 | |
| Quick Ratio | 3.9 | 7.0 | · | 2.2 | 2.6 | 1.5 | · | 1.7 | 1.9 | 2.6 | · | 5.0 | 4.2 | 6.1 | · | 3.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.1 | · | 0.0 | |
| Receivables Turnover | 1.1 | 0.2 | · | 1.0 | 2.8 | 1.0 | · | 0.4 | 0.5 | 0.2 | · | 0.4 | 0.3 | 1.1 | · | 0.8 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.13 | $2.24 | · | $4.26 | $4.47 | $4.67 | · | $5.27 | $5.73 | $6.20 | · | $6.25 | $6.63 | $7.39 | · | $2.91 | |
| Revenue / Share | $0.06 | $0.03 | · | $0.36 | $0.63 | $0.36 | · | $0.21 | $0.25 | $0.13 | · | $0.23 | $0.10 | $0.53 | · | $0.04 | |
| Cash Flow / Share | · | $-0.61 | · | · | · | $-0.05 | · | · | · | $-0.49 | · | · | · | $-1.25 | · | · | |
| Cash / Share | $2.51 | $3.34 | · | $0.86 | $1.31 | $1.10 | · | $1.76 | $1.00 | $1.62 | · | $1.39 | $2.10 | $2.83 | · | $1.56 | |
| EPS (TTM) | $-2.02 | $-1.37 | · | $-0.85 | $-0.98 | $-1.50 | · | $-1.48 | $-1.50 | $-1.77 | · | $3.24 | $2.93 | $2.72 | · | $-3.83 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $81M | · | $134M | $123M | $93M | · | $62M | $63M | $50M | · | $462M | $448M | $446M | · | $30M | |
| Net Income TTM | $-150M | $-103M | · | $-63M | $-74M | $-114M | · | $-114M | $-113M | $-126M | · | $205M | $186M | $173M | · | $-224M | |
| Market Cap | $1.87B | $1.83B | · | $1.28B | $939M | $829M | · | $873M | $603M | $744M | · | $431M | $585M | $579M | · | $379M | |
| P/E | -12.9 | -18.3 | · | -20.1 | -12.8 | -7.9 | · | -8.5 | -5.7 | -5.9 | · | 2.0 | 2.9 | 3.3 | · | -1.6 | |
| P/S | 50.3 | 22.5 | · | 9.5 | 7.6 | 8.9 | · | 14.0 | 9.6 | 14.7 | · | 0.9 | 1.3 | 1.3 | · | 12.7 | |
| P/B | 23.2 | 11.2 | · | 4.0 | 2.8 | 2.6 | · | 2.4 | 1.5 | 1.7 | · | 1.0 | 1.3 | 1.2 | · | 2.1 | |
| P / Tangible Book | 27.7 | 12.2 | · | 4.2 | 2.9 | 2.7 | · | 2.5 | 1.6 | 1.8 | · | 1.1 | 1.4 | 1.3 | · | 2.4 | |
| P / Cash Flow | · | -40.0 | · | · | · | -243.3 | · | · | · | -19.7 | · | · | · | -7.0 | · | · | |
| Earnings Yield | -7.7% | -5.5% | · | -5.0% | -7.8% | -12.6% | · | -11.8% | -17.6% | -16.8% | · | 51.1% | 33.9% | 30.1% | · | -62.3% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $106M | $76M | $76M | $412M | $27M |
| Operating Margin % | -87.3% | -179.7% | -181.6% | · | · |
| Net Income | $-81M | $-123M | $-119M | $124M | $-212M |
| Diluted EPS | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 5.9 | 3.4 | 7.4 | · | · |
| Quick Ratio | 1.1 | 1.4 | 7.1 | · | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-35M | $-112M | $-121M | · | · |
Institutional owners (13F) 212 filers · $1.9B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
212
Value held
$1.9B
New positions
22
Exited positions
31
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 22 (-20 vs prior Q) | 31 (0 vs prior Q) | 59 (-16 vs prior Q) | 73 (+13 vs prior Q) | -2.0M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| EcoR1 Capital, LLC | $600,445,942 | 22,970,388 | 32.29% | Shares |
| Rubric Capital Management LP | $182,980,000 | 7,000,000 | 9.84% | Shares |
| BlackRock, Inc. | $111,121,925 | 4,251,030 | 5.98% | Shares |
| PERCEPTIVE ADVISORS LLC | $109,342,391 | 4,182,953 | 5.88% | Shares |
| BVF INC/IL | $95,388,572 | 3,649,142 | 5.13% | Shares |
| VANGUARD GROUP INC | $61,315,382 | 2,328,727 | 3.30% | Shares |
| MORGAN STANLEY | $58,325,141 | 2,231,260 | 3.14% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $46,558,373 | 1,781,116 | 2.50% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $40,752,208 | 1,558,998 | 2.19% | Shares |
| Assenagon Asset Management S.A. | $32,727,986 | 1,252,027 | 1.76% | Shares |
| Nextech Invest Ltd. | $29,118,548 | 1,113,946 | 1.57% | Shares |
| STATE STREET CORP | $28,445,966 | 1,088,216 | 1.53% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $25,995,770 | 994,955 | 1.40% | Shares |
| CITADEL ADVISORS LLC | $23,895,516 | 914,136 | 1.29% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $23,259,000 | 889,802 | 1.25% | Shares |
| FMR LLC | $18,365,133 | 702,568 | 0.99% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $18,099,012 | 692,410 | 0.97% | Shares |
| Prosight Management, LP | $17,629,705 | 674,434 | 0.95% | Shares |
| Qube Research & Technologies Ltd | $15,516,443 | 593,590 | 0.83% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13,332,236 | 510,032 | 0.72% | Shares |
| Redmile Group, LLC | $12,851,836 | 491,654 | 0.69% | Shares |
| Capricorn Fund Managers Ltd | $12,717,868 | 486,529 | 0.68% | Shares |
| GOLDMAN SACHS GROUP INC | $12,307,288 | 470,822 | 0.66% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $10,939,512 | 418,497 | 0.59% | Shares |
| DEUTSCHE BANK AG\ | $10,382,547 | 397,190 | 0.56% | Shares |
| Hillsdale Investment Management Inc. | $10,009,581 | 382,922 | 0.54% | Shares |
| FIRST TRUST ADVISORS LP | $8,897,088 | 340,363 | 0.48% | Shares |
| Granahan Investment Management, LLC | $8,787,144 | 336,157 | 0.47% | Shares |
| NORTHERN TRUST CORP | $8,392,849 | 321,073 | 0.45% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $7,997,401 | 319,385 | 0.43% | Shares |
| Pictet Asset Management Holding SA | $7,446,189 | 308,187 | 0.40% | Shares |
| PICTON MAHONEY ASSET MANAGEMENT | $7,092,908 | 271,343 | 0.38% | Shares |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5,849,243 | 223,766 | 0.31% | Shares |
| BANK OF AMERICA CORP /DE/ | $5,726,515 | 219,071 | 0.31% | Shares |
| WELLS FARGO & COMPANY/MN | $5,677,573 | 217,199 | 0.31% | Shares |
| SummitTX Capital, L.P. | $5,510,364 | 210,802 | 0.30% | Shares |
| Man Group plc | $5,509,763 | 210,779 | 0.30% | Shares |
| FEDERATED HERMES, INC. | $4,914,190 | 187,995 | 0.26% | Shares |
| RAYMOND JAMES FINANCIAL INC | $4,350,114 | 166,416 | 0.23% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $4,066,835 | 155,579 | 0.22% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3,984,154 | 152,416 | 0.21% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $3,800,390 | 145,386 | 0.20% | Shares |
| D. E. Shaw & Co., Inc. | $3,785,255 | 144,807 | 0.20% | Shares |
| DIADEMA PARTNERS LP | $3,715,330 | 142,132 | 0.20% | Shares |
| CITIGROUP INC | $3,435,868 | 131,441 | 0.18% | Shares |
| Bank of New York Mellon Corp | $3,427,107 | 131,106 | 0.18% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3,408,656 | 130,400 | 0.18% | Call option |
| XTX Topco Ltd | $3,290,425 | 125,877 | 0.18% | Shares |
| Nuveen, LLC | $3,120,829 | 119,389 | 0.17% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $3,100,282 | 118,603 | 0.17% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. ×8 filings | Nov. 19, 2025 | 30.70% | Amendment | Board campaign | SEC |
| All Blue Falcons FZE, Daniel Edward Llewellen Cookson ×2 filings | Dec. 28, 2022 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 28 insiders · 12 officers · 17 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kenneth Galbraith | Chair & CEO | Jan. 12, 2026 A | 226,842 | 0 | 4 | $-3,337,929 |
| Kristin Stafford | EVP, Chief Financial Officer | April 6, 2026 A | · | 0 | 0 | $0 |
| Christopher Astle | SVP & Chief Financial Officer | Jan. 5, 2024 A | 6,503 | 0 | 0 | $0 |
| Neil A Klompas | President & COO | March 10, 2023 M | 17,032 | 0 | 0 | $0 |
| Mark Hollywood | EVP & Chief Operating Officer | July 6, 2026 A | 133,852 | 0 | 1 | $-138,740 |
| Paul R Schneider | EVP, General Counsel | May 13, 2026 A | · | 0 | 0 | $0 |
| Adam Schayowitz | EVP, Head of Research & Development | April 9, 2026 A | · | 0 | 0 | $0 |
| Scott Platshon | EVP, Chief Business Officer | April 9, 2026 A | · | 0 | 0 | $0 |
| Paul Andrew Moore | Chief Scientific Officer | Jan. 12, 2026 A | 48,497 | 0 | 3 | $-721,486 |
| Jeffrey T L Smith | EVP & Chief Medical Officer | Jan. 12, 2026 M | 26,708 | 0 | 2 | $-475,562 |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | Jan. 6, 2026 A | 459 | 0 | 0 | $0 |
| Neil Josephson | Chief Medical Officer | Nov. 10, 2022 M | 14,449 | 0 | 0 | $0 |
| Gregory A. Ciongoli | Director | Jan. 12, 2026 A | 488,500 | 0 | 0 | $0 |
| Alessandra Cesano | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| Carlos Campoy | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| Robert E Landry | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| Kelvin Neu | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| Susan Mahony | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| Brian N Cherry | Director | Jan. 12, 2026 A | · | 0 | 0 | $0 |
| EcoR1 Capital, LLC | Director | Jan. 17, 2025 P | 15,720,161 | 0 | 0 | $0 |
| Nancy Davidson | Director | Dec. 10, 2024 A | · | 0 | 0 | $0 |
| Neil Gallagher | Director | Dec. 10, 2024 A | · | 0 | 0 | $0 |
| Derek John Michael Miller | Director | Dec. 10, 2024 A | · | 0 | 0 | $0 |
| Troy Cox | Director | Dec. 10, 2024 A | · | 0 | 0 | $0 |
| Kenneth J. Hillan | Director | Dec. 7, 2023 A | · | 0 | 0 | $0 |
| Hollings Renton | Director | Dec. 7, 2023 A | · | 0 | 0 | $0 |
| Natalie Sacks | Director | Dec. 21, 2022 A | · | 0 | 0 | $0 |
| Lota S. Zoth | Director | Dec. 21, 2022 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 30 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.32% | 59,315 NS | July 31, 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.15% | 14,705 SH | Oct. 1, 2026 | Daily |
| IBB · iShares Trust | 0.14% | 537,742 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.12% | 5,008 SH | Oct. 1, 2026 | Daily |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.11% | 65,877 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.10% | 74,514 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.08% | 439,290 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.07% | 50,443 SH | Aug. 19, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.07% | 68,050 SH | Oct. 1, 2026 | Daily |
| IWM · iShares Trust | 0.04% | 1,202,863 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 270,692 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.03% | 22,528 NS | July 31, 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.03% | 189,632 NS | July 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.02% | 5,969 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.02% | 5,910 SH | Sept. 11, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 18,267 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 3,039 SH | Sept. 11, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 110,298 SH | Aug. 19, 2026 | Daily |
| TILT · FlexShares Trust | 0.01% | 5,508 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 70,572 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 3,968 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 12,951 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.00% | 14,406 SH | Sept. 10, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.00% | 8,364 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.00% | 130 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,508,613 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 4,085 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 1,999 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 5,753 SH | Sept. 11, 2026 | Daily |
| SMMV · iShares Trust | · | 16,029 SH | Aug. 19, 2026 | Daily |
ZYME Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 18 analysts
BUY
Median target
$38.00
+51.1%
6 33.3%
Strong Buy
11 61.1%
Buy
1 5.6%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
13 analysts · 2026-09-27Mean target $41.23 +63.9%
← Below all targets
Current price $25.15
Low$32.00
Mean$41.23
High$60.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026